Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001).

scientific article published in August 2003

Trends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001). is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S0732-8893(03)00086-5
P698PubMed publication ID12944017

P50authorMateu EspasaQ73874855
P2093author name stringJ A Martínez
J Mensa
F Marco
M Almela
M T Jiménez de Anta
J Puig de la Bellacasa
A Jurado
C Danés
P2860cites workIn vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungiQ28343817
Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformansQ28379123
In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida sppQ28379320
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobiaQ30453797
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.Q33980029
Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.Q34085884
In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.Q35134781
Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patientsQ35819117
Opportunistic mycoses in the immunocompromised host: experience at a cancer center and reviewQ35997161
The new fungal opportunists are comingQ41044994
The epidemiology of candidemia in two United States cities: results of a population-based active surveillanceQ41696774
Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with FluconazoleQ43543160
Candida parapsilosis Fungemia Associated with Implantable and Semi-Implantable Central Venous Catheters and the Hands of Healthcare WorkersQ63197408
The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceQ71181685
Evolving risk factors for invasive fungal infections--all neutropenic patients are not the sameQ72160665
International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant GroupQ73102772
The epidemiology of hematogenous candidiasis caused by different Candida speciesQ73441200
Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida sppQ77474976
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectvoriconazoleQ412236
P304page(s)259-264
P577publication date2003-08-01
P1433published inDiagnostic Microbiology and Infectious DiseaseQ15763479
P1476titleTrends in frequency and in vitro susceptibilities to antifungal agents, including voriconazole and anidulafungin, of Candida bloodstream isolates. Results from a six-year study (1996-2001)
P478volume46

Reverse relations

cites work (P2860)
Q46885843(B1) Candida and mycotic infections
Q38175195A single center's experience with Candida parapsilosis related long-term central venous access device infections: the port removal decision and its outcomes
Q45084559Anidulafungin
Q34036214Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
Q42846025Antifungal drug susceptibility profile of Pichia anomala isolates from patients presenting with nosocomial fungemia.
Q41909634Are Anidulafungin or Voriconazole Released from Polymethylmethacrylate In Vitro?
Q34719843Candida guilliermondii fungemia in patients with hematologic malignancies
Q34852747Candida parapsilosis, an emerging fungal pathogen
Q37613000Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility
Q91983100Candida parapsilosis: from Genes to the Bedside
Q55379370D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections.
Q36441524Echinocandin antifungals: review and update
Q36458402Emerging echinocandins for treatment of invasive fungal infections
Q40458611Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain.
Q36308069Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital.
Q40757551Epidemiology of candidaemia in a tertiary care university hospital: 10-year experience with 381 candidaemia episodes between 2001 and 2010.
Q43250363High incidence of Candida parapsilosis candidaemia in non-neutropenic critically ill patients: epidemiology and antifungal susceptibility.
Q37608276New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance
Q36491819Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations
Q33910250One year prospective survey of Candida bloodstream infections in Scotland.
Q34303424Oropharyngeal Candida colonization in human immunodeficiency virus infected patients
Q42284150Pharmacokinetics of fosfluconazole and fluconazole following multiple intravenous administration of fosfluconazole in healthy male volunteers
Q35587733The diagnosis of hepatosplenic candidiasis by DNA analysis of tissue biopsy and serum
Q35166823Voriconazole in the management of nosocomial invasive fungal infections